Heart Failure
RSSArticles
-
AAP Recommends Screening All Children for Heart Problems
Around 2,000 Americans younger than age 25 die each year because of sudden cardiac death. -
Time of the Essence with Dapagliflozin for Heart Failure
By adding dapagliflozin to maximally tolerated standard therapy for heart failure with reduced left ventricular ejection fraction, researchers noted the reduction in mortality and recurrent heart failure began within one month of starting this therapy. -
Is Empagliflozin Safe in Combination with a Neprilysin Inhibitor for Heart Failure?
A prespecified subgroup analysis of heart failure patients with reduced ejection fraction who were on neprilysin inhibitors before empagliflozin was administered (vs. those not on neprilysin inhibitors) showed the reduction in mortality and hospital admissions for heart failure was not attenuated by concurrent neprilysin use.
-
Low BNP Levels in Up to 16% of Heart Failure Patients
In patients with clinical heart failure and low B-type natriuretic peptide levels, the authors found these patients usually are young and obese, with higher ejection fraction and better renal function.
-
Low BNP Levels in Up to 16% of Heart Failure Patients
In patients with clinical heart failure and low B-type natriuretic peptide levels, the authors found these patients usually are young and obese, with higher ejection fraction and better renal function.
-
Can Left Ventricular Strain Detect Early Cardiac Toxicity of Cancer Chemotherapy?
Using left ventricular peak systolic global longitudinal strain vs. left ventricular ejection fraction to survey patients undergoing potentially cardiotoxic chemotherapy with at least one other risk factor for heart failure showed no difference in the primary endpoint of the difference in ejection fraction between the two groups at one year.
-
Is Empagliflozin Safe in Combination with a Neprilysin Inhibitor for Heart Failure?
A prespecified subgroup analysis of heart failure patients with reduced ejection fraction who were on neprilysin inhibitors before empagliflozin was administered (vs. those not on neprilysin inhibitors) showed the reduction in mortality and hospital admissions for heart failure were not attenuated by concurrent neprilysin use.
-
Vericiguat Tablets (Verquvo)
Vericiguat is indicated to lower the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.
-
Statins as a Protector Against Chemotherapy
Women with early stage breast cancer shield their hearts with cholesterol-lowering drug.
-
Using Sacubitril/Valsartan to Treat Heart Failure with Preserved Ejection Fraction
An analysis of renal outcomes in the PARAGON-HF trial revealed sacubitril/valsartan slows progression of kidney disease in patients with heart failure with preserved ejection fraction compared to valsartan alone.